Saint-Gobain Medical Quality
FDA Aligns 21 CFR 820 with ISO 13485:2016 
Written by
Dannelle Lao
Published on
08 July 2025
Reading time
2 minutes
File under
Table of contents
Article contributed by
Author
Dannelle Lao
Listen to this article

FDA Aligns 21 CFR 820 with ISO 13485:2016 

What It Means for Medical Device Manufacturers

In a significant move toward global regulatory harmonization, the U.S. Food and Drug Administration (FDA) has finalized amendments to 21 CFR Part 820, aligning its Quality System Regulation (QSR) with ISO 13485:2016. This change, effective February 2026, marks a pivotal shift in how medical device manufacturers approach quality management systems (QMS) in the U.S.

What’s Changing?

The core update is the incorporation by reference of ISO 13485:2016 as the foundation for QMS requirements under the newly titled Quality Management System Regulation (QMSR). This alignment reflects FDA’s determination that ISO 13485 is substantially similar to the existing QSR and provides a comparable level of assurance in the safety and effectiveness of medical devices.

Why This Matters

The FDA’s rationale is clear:

  • Global Harmonization: Aligning with international standards reduces regulatory fragmentation.
  • Risk-Based Focus: ISO 13485 emphasizes risk management throughout the product lifecycle.
  • Efficiency Gains: Manufacturers can expect reduced costs and faster time-to-market for new devices.

Key Benefits for the Industry

  • Streamlined Compliance: One standard, multiple markets.
  • Improved Risk Management: Integrated into every phase of the device lifecycle.
  • Faster Approvals: Harmonized standards mean fewer regulatory hurdles.
  • Data-Driven Quality: Encourages a systematic, evidence-based approach to compliance.

Challenges to Consider

While the alignment is a step forward, it’s not without complexity:

  • ISO 13485 Certification Not Required: Compliance with 21 CFR 820 doesn’t mandate ISO certification.
  • FDA Inspections Still Apply: Certification doesn’t exempt manufacturers from FDA oversight.
  • QSIT Overhaul Pending: The FDA’s inspection technique will be updated, but the timeline remains uncertain.

Inspection Readiness: What’s New?

Manufacturers should prepare for:

  • Stricter Documentation Requirements: Records must be retrievable within two days.
  • No More Exemptions: Management reviews, internal audits, and supplier audits are now mandatory and subject to inspection.
  • Updated Definitions and Structure: The revised regulation is more concise, with ISO 13485 incorporated under § 820.7.

Proactive in Our Approach

All FDA-registered Saint-Gobain sites are already ISO 13485:2016 certified. We are actively working to ensure full alignment with the revised QMSR well ahead of the February 2026 deadline. This proactive stance reinforces our commitment to quality, compliance, and customer trust. The FDA’s final rule represents a major step toward a more unified global regulatory environment. For manufacturers, it’s an opportunity to modernize quality systems, reduce duplication, and enhance product safety and performance.

For more details, you can view the full regulation update on the Federal Register.  

Related Regulatory Content